Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®

Phase 1CompletedNCT01725620

LG Life Sciences48 enrolled

Overview

To compare the pharmacokinetic characteristic of LBEC0101 25mg with active comparator, Enbrel® 25mg.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

LBEC0101 (Etanercept 25mg)DRUG

Enbrel (Etanercept 25mg)DRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy males, 20 to 45 years of age the moment of screening * Body mass index is between 18.0 and 30.0 kg/m Exclusion Criteria: * The tuberculosis patient of latent tuberculosis patient * Hypersensitivity response to the test and comparator drugs

Locations (1)

Seoul National University Hospital, Clinical Trial Center

Seoul, Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.